Stock Analiz

Definium Therapeutics, Inc. DFTX

Medicinal Chemicals and Botanical Products · data as of November 13, 2026

$32.08Market cap $4.4B
Open the interactive analysis →

Definium Therapeutics, Inc. (DFTX) is a healthcare company listed in the US with a market value of about $4.4B.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -50%.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B4.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-50.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue——————
Net income-$184M-$109M-$96M-$57M-$93M-$34M
Free cash flow——————
EPS (diluted)$-2.06$-1.54$-2.44$-1.84$-3.40$-0.13
Net margin——————
ROIC-44.5%-31.2%-79.6%-34.7%-61.1%-34.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 18 analysts is $72.78, 127% above the current price; targets range from $55.00 to $91.00; the consensus rating is “Strong buy”; expected EPS is $-2.90 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Definium Therapeutics pay a dividend?

Not currently.

Is Definium Therapeutics a good stock to buy?

We do not give buy or sell advice. Definium Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

PMPhilip Morris International1.6BTIBritish American Tobacco p.l.c.2.2MOAltria Group2.8RGCRegencell Bioscience Holdings0.4RLXRLX Technology3.2TRLVTrulieve Cannabis1.6

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.